摘要
目的系统回顾中医药治疗慢性阻塞性肺疾病(COPD)经济学评价研究相关文献,分析研究中存在的主要问题并提出建议,为规范药物经济学评价研究提供借鉴。方法计算机检索中国知网、维普网和PubMed等数据库自建库至2023年8月1日中医药治疗COPD经济学评价研究相关文献。对纳入文献从研究角度、成本类型和分析方法等方面进行描述性分析,并评价文献质量。结果共纳入9篇文献,均为高质量文献(标准符合率≥75%)。纳入研究均表明中医药治疗COPD具有经济性。干预措施包括药物治疗和中医特色治疗。仅3项研究明确了研究角度。仅2项研究的成本类型为直接成本和间接成本,多数研究为直接成本。仅3项研究的分析方法为成本效用分析,多数研究为成本效果分析。仅3项研究的产出指标为健康效用值,多数研究为有效率。仅3项研究为模型法研究,使用了Markov或联合决策树模型,模型参数均源于文献。所有研究均进行了单因素敏感性分析。结论现有的中医药治疗COPD经济学评价研究数量较少,且存在研究角度不明确、成本测算范围小、分析方法与健康产出指标选择不恰当、研究时限普遍较短、模型法运用较少的问题,建议未来开展的中医药治疗COPD经济学评价研究结合我国实际情况对评价方法和工具进行完善,积极且规范化开展药物经济学评价研究,为COPD治疗方案的优化提供科学客观的决策依据。
Objective This paper aims to systematically review economic evaluation studies on traditional Chinese medicine(TCM)treatment for chronic obstructive pulmonary disease(COPD),analyze the main issues in these studies,and provide recommendations for standardizing economic evaluation research on medication.Methods Chinese databases(CNKI,VIP)and international database(PubMed)were searched from the inception of the databases to August 1,2023,for economic evaluation studies on TCM treatment for COPD.Descriptive analysis was conducted on the included literature from the perspectives of research design,cost types,and analysis methods,and the quality of the literature was evaluated.Results A total of 9 articles were included,all of which were of high quality(compliance rate≥75%).The included studies all indicated the cost-effectiveness of TCM treatment for COPD.The intervention measures included medication therapy and TCM characteristic treatment.Only 3 studies explicitly stated their research perspectives.Only 2 studies considered both direct and indirect costs,while most studies focused on direct costs.Only 3 studies used cost-utility analysis as the analysis method,while most studies used cost-effectiveness analysis.Besides,only 3 studies used health utility values as the outcome measure,while most studies used efficacy measures.Only 3 studies employed modeling methods,using Markov or joint decision tree models,and the model parameters were derived from the literature.All studies performed one-way sensitivity analysis.Conclusion The number of existing economic evaluation studies on TCM treatment for COPD is limited,and there are issues such as unclear research perspectives,limited scope of cost calculation,inappropriate choice of analysis methods and health outcome measures,generally short study duration,and limited use of modeling methods.Here,we recommended that future economic evaluation studies on TCM treatment for COPD should improve evaluation methods and tools based on the actual situation in China,actively and
作者
刘紫萱
朱嘉欣
何素珍
蒙晓
陈一帆
豆志州
魏理
Liu Zixuan;Zhu Jiaxin;He Suzhen;Meng Xiao;Chen Yifan;Dou Zhizhou;Wei Li(Department of Pharmacy,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;School of Pharmaceutical Sciences,Guangzhou Medical University,Guangzhou 511436,China)
出处
《保健医学研究与实践》
2024年第2期127-135,共9页
Health Medicine Research and Practice
基金
广东省基础与应用基础研究基金项目(No.2021A1515220096)
市校(院)联合资助项目基础与应用基础研究(No.202201020448)。
关键词
药物经济学
中医药
慢性阻塞性肺疾病
系统评价
Pharmacoeconomics
Traditional Chinese medicine
Chronic obstructive pulmonary disease
Systematic review
